Findings from this study highlight the significance of IL-6-DNMT3b–mediated signaling as a potential therapeutic target for patients with HCC exhibiting cancer stemness-related properties and sorafenib resistance. This evidence concerns the gene IL6 and hepatocellular carcinoma.